Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma

NCT: NCT03444948 · SUSPENDED

NCT IDNCT03444948
StatusSUSPENDED
Start Date2019-02-14
Completion2028-12-01

Brief Summary

To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients with inoperable pancreatic cancer confers survival benefit when compared to patients receiving standard medical care.

Frequently Asked Questions

What is A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma?

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma is a clinical trial registered under NCT03444948. Current status: SUSPENDED.

What is the status of NCT03444948?

The current status of NCT03444948 (A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma) is: SUSPENDED.

When did A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma start?

A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma started on 2019-02-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑